Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for
potentially curable neoplasms such as acute lymphoblastic leukemia. In multiple myeloma …

1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

The European Myeloma Network (EMN) organized two flow cytometry workshops. The first
aimed to identify specific indications for flow cytometry in patients with monoclonal …

Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients
have over 10 years overall survival. Using modern combination therapies—with or without …

Standard first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem
cell transplantation is melphalan plus prednisone (MP). However, complete responses …

Purpose We investigated the effect on minimal residual disease, by qualitative and real-time
quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included …

Purpose To investigate the impact of immunophenotypic response (IR) versus complete
response (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR) in …

The article presents the revised and updated guidelines on the diagnosis and management
of multiple myeloma. It includes new sections on imaging and the management skeletal …

We have analyzed the applicability, sensitivity and prognostic value of allele-specific
oligonucleotide real-time quantitative PCR (ASO RQ-PCR) as a method for minimal residual …

In multiple myeloma (MM), the impact of complete response (CR) could be shown only after
introduction of high-dose therapy plus autologous stem cell transplantation (ASCT). In the …